5 Best Stem Cell Therapy Stocks to Buy

4. Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stem cell therapy stocks to buy. Gilead Sciences, Inc. (NASDAQ:GILD) announced on April 17 the attainment of all required regulatory approvals for its previously announced acquisition of Arcellx. The company also stated that it has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.

In a separate development, Gilead Sciences, Inc. (NASDAQ:GILD) received a rating update from Truist on April 8, with the firm lifting the price target on the stock to $155 from $152 while reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 earnings in Biotech, with the firm stating that reactivity to regulatory and policy shifts across the sector is continuing to ease.

Truist also noted a recent pickup in deal activity, which it believes holds the potential to build momentum through the remainder of the year into midterms. The firm further told investors in a research note that for Gilead Sciences, Inc. (NASDAQ:GILD), it is looking for its management commentary on Yeztugo launch strategy and payer access dynamics in the U.S./EU markets, along with any anito-cel launch preparation updates ahead of the December 23, 2026, PDUFA.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs, and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.